Listed drug maker AFT Pharmaceuticals said it was sticking with the development of its drug Pascomer despite a disappointing study result and the withdrawal of its US licencee.
The clinical study of the use of Pascomer as a topical treatment for facial angiofibromas (FAs), which often develop from
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
